Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Articles

Company's annual Commercial Summit updates Veeva Vault CRM status, along with AI partnerships.

Veeva Rolls Out New Features While Transitioning Its CRM platform

The latest news for pharma industry insiders.

Pharma Pulse 5/8/24: Navigating the Long, Bumpy Road to Rare Disease Diagnosis and Treatment, ‘Deepfake’ Detector to Disinformation & more

The latest accreditation further establishes the company’s reputation in the pharma and healthcare logistics space.

Geodis’ Copenhagen Plant Awarded IATA CEIV Pharma Certification 

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages. 

Myonex Finalizes Creapharm Deal

Pharma Pulse 5/7/24: Biosimilars May Save Money — But What About Out-of-Pockets? How Diverse Skills Can Drive Success in Biotech & more

Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.

The Promise of RFID for Improving Medication Inventory Management

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Martin Hawes, Global Head of Product Development, Tower Cold Chain offers insights on the future of cell & gene therapies when it comes to cold chain storage. 

LogiPharma Europe 2024: Tower Cold Chain Global Head of Product Development Discusses the Future of Cell & Gene Therapy and Cold Chain Storage

Pharma Pulse 5/6/24: Are Smartphones Driving Teens to Depression? Does Pharma Know What Their Customers Really Want? & more

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met. 

Astellas, Poseida Therapeutics Ink Allogeneic Cell Therapy Agreement

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right